Abid Qureshi

Abid Qureshi

Auto-generated profile, based on publicly available information

Abid Qureshi

Department of Biotechnology, University of Kashmir, Srinagar, India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2012 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
NTNishant Thakur
Nishant Thakur
AQAbid Qureshi
Abid Qureshi
MKManoj Kumar
Manoj Kumar
In the battle against viruses, antiviral peptides (AVPs) had demonstrated the immense potential. Presently, more than 15 peptide-based drugs are in various stages of clinical trials. Emerging and re-emerging viruses further emphasize the efforts to accelerate antiviral drug discovery efforts. Despite, huge importance of the field, no dedicated AVP resource is available. In the present study, we have collected 1245 peptides which were experimentally checked for antiviral activity targeting important human viruses like influenza, HIV, HCV and SARS, etc. After removing redundant peptides, 1056 peptides were divided into 951 training and 105 validation data sets. We have exploited various peptides sequence features, i.e. motifs and alignment followed by amino acid composition and physicochemical properties during 5-fold cross validation using Support Vector Machine. Physiochemical properties-based model achieved maximum 85% accuracy and 0.70 Matthew’s Correlation Coefficient (MCC). Performance of this model on the experimental validation data set showed 86% accuracy and 0.71 MCC which is far better than the general antimicrobial peptides prediction methods. Therefore, AVPpred—the first web server for predicting the highly effective AVPs would certainly be helpful to researchers working on peptide-based antiviral development. The web server is freely available at http://crdd.osdd.net/servers/avppred.

26 November 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AQAbid Qureshi
Abid Qureshi
NTNishant Thakur
Nishant Thakur
HTHimani Tandon
Himani Tandon
MKManoj Kumar
Manoj Kumar
Antiviral peptides (AVPs) have exhibited huge potential in inhibiting viruses by targeting various stages of their life cycle. Therefore, we have developed AVPdb, available online at http://crdd.osdd.net/servers/avpdb, to provide a dedicated resource of experimentally verified AVPs targeting over 60 medically important viruses including Influenza, HCV, HSV, RSV, HBV, DENV, SARS, etc. However, we have separately provided HIV inhibiting peptides in ‘HIPdb’. AVPdb contains detailed information of 2683 peptides, including 624 modified peptides experimentally tested for antiviral activity. In modified peptides a chemical moiety is attached for increasing their efficacy and stability. Detailed information include: peptide sequence, length, source, virus targeted, virus family, cell line used, efficacy (qualitative/quantitative), target step/protein, assay used in determining the efficacy and PubMed reference. The database also furnishes physicochemical properties and predicted structure for each peptide. We have provided user-friendly browsing and search facility along with other analysis tools to help the users. Entering of many synthetic peptide-based drugs in various stages of clinical trials reiterate the importance for the AVP resources. AVPdb is anticipated to cater to the needs of scientific community working for the development of antiviral therapeutics.

24 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AQAbid Qureshi
Abid Qureshi
NTNishant Thakur
Nishant Thakur
MKManoj Kumar
Manoj Kumar
Besides antiretroviral drugs, peptides have also demonstrated potential to inhibit the Human immunodeficiency virus (HIV). For example, T20 has been discovered to effectively block the HIV entry and was approved by the FDA as a novel anti-HIV peptide (AHP). We have collated all experimental information on AHPs at a single platform. HIPdb is a manually curated database of experimentally verified HIV inhibiting peptides targeting various steps or proteins involved in the life cycle of HIV e.g. fusion, integration, reverse transcription etc. This database provides experimental information of 981 peptides. These are of varying length obtained from natural as well as synthetic sources and tested on different cell lines. Important fields included are peptide sequence, length, source, target, cell line, inhibition/IC50, assay and reference. The database provides user friendly browse, search, sort and filter options. It also contains useful services like BLAST and ‘Map’ for alignment with user provided sequences. In addition, predicted structure and physicochemical properties of the peptides are also included. HIPdb database is freely available at http://crdd.osdd.net/servers/hipdb. Comprehensive information of this database will be helpful in selecting/designing effective anti-HIV peptides. Thus it may prove a useful resource to researchers for peptide based therapeutics development.

15 April 2018 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
AQAbid Qureshi
Abid Qureshi
VTVaqar Gani Tantray
Vaqar Gani Tantray
AKAltaf Rehman Kirmani
Altaf Rehman Kirmani
AAAbdul Ghani Ahangar
Abdul Ghani Ahangar

1 January 2014 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
AQAbid Qureshi
Abid Qureshi
NTNishant Thakur
Nishant Thakur
IMIsha Monga
Isha Monga
ATAnamika Thakur
Anamika Thakur
MKManoj Kumar
Manoj Kumar
Viral microRNAs (miRNAs) regulate gene expression of viral and/or host genes to benefit the virus. Hence, miRNAs play a key role in host–virus interactions and pathogenesis of viral diseases. Lately, miRNAs have also shown potential as important targets for the development of novel antiviral therapeutics. Although several miRNA and their target repositories are available for human and other organisms in literature, but a dedicated resource on viral miRNAs and their targets are lacking. Therefore, we have developed a comprehensive viral miRNA resource harboring information of 9133 entries in three subdatabases. This includes 1308 experimentally validated miRNA sequences with their isomiRs encoded by 44 viruses in viral miRNA ‘VIRmiRNA’ and 7283 of their target genes in ‘VIRmiRtar’. Additionally, there is information of 542 antiviral miRNAs encoded by the host against 24 viruses in antiviral miRNA ‘AVIRmir’. The web interface was developed using Linux-Apache-MySQL-PHP (LAMP) software bundle. User-friendly browse, search, advanced search and useful analysis tools are also provided on the web interface. VIRmiRNA is the first specialized resource of experimentally proven virus-encoded miRNAs and their associated targets. This database would enhance the understanding of viral/host gene regulation and may also prove beneficial in the development of antiviral therapeutics. Database URL: http://crdd.osdd.net/servers/virmirna

25 July 2015 in Peptide Science
Verified
Journal Article
Open access
PDF file
AQAbid Qureshi
Abid Qureshi
HTHimani Tandon
Himani Tandon
MKManoj Kumar
Manoj Kumar
Peptide‐based antiviral therapeutics has gradually paved their way into mainstream drug discovery research. Experimental determination of peptides' antiviral activity as expressed by their IC 50 values involves a lot of effort. Therefore, we have developed “AVP‐IC 50 Pred,” a regression‐based algorithm to predict the antiviral activity in terms of IC 50 values (μM). A total of 759 non‐redundant peptides from AVPdb and HIPdb were divided into a training/test set having 683 peptides (T 683 ) and a validation set with 76 independent peptides (V 76 ) for evaluation. We utilized important peptide sequence features like amino‐acid compositions, binary profile of N8‐C8 residues, physicochemical properties and their hybrids. Four different machine learning techniques (MLTs) namely Support vector machine, Random Forest, Instance‐based classifier, and K‐Star were employed. During 10‐fold cross validation, we achieved maximum Pearson correlation coefficients (PCCs) of 0.66, 0.64, 0.56, 0.55, respectively, for the above MLTs using the best combination of feature sets. All the predictive models also performed well on the independent validation dataset and achieved maximum PCCs of 0.74, 0.68, 0.59, 0.57, respectively, on the best combination of feature sets. The AVP‐IC 50 Pred web server is anticipated to assist the researchers working on antiviral therapeutics by enabling them to computationally screen many compounds and focus experimental validation on the most promising set of peptides, thus reducing cost and time efforts. The server is available at http://crdd.osdd.net/servers/ic50avp . © 2015 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 104: 753–763, 2015.